Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.
Blood Rev
; : 101240, 2024 Sep 04.
Article
in En
| MEDLINE
| ID: mdl-39245607
ABSTRACT
The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) presents distinct therapeutic challenges and benefits. In PAH, the benefits of oral anticoagulation are uncertain, with studies yielding mixed results on their efficacy and safety. Conversely, oral anticoagulants are a cornerstone in the treatment of CTEPH, where their use is consistently recommended to prevent recurrent thromboembolic events. The choice between vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) remains a significant clinical question, as each type presents advantages and potential drawbacks. Furthermore, drug-drug interactions (DDIs) with concomitant PAH and CTEPH treatments complicate anticoagulant management, necessitating careful consideration of individual patient regimens. This review examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of DDIs within a context of multi-drug treatments, including targeted drugs in PAH.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Blood Rev
/
Blood rev
/
Blood reviews
Journal subject:
HEMATOLOGIA
Year:
2024
Document type:
Article
Country of publication:
Reino Unido